Last reviewed · How we verify
Paxlovid (Copackaged) — Competitive Intelligence Brief
marketed
Immunology
Live · refreshed every 30 min
Target snapshot
Paxlovid (Copackaged) (nirmatrelvir) — Pfizer. Paxlovid works by binding to the main protease enzyme of the SARS-CoV-2 virus, preventing it from replicating.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Paxlovid (Copackaged) TARGET | nirmatrelvir | Pfizer | marketed | 2023-01-01 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
- — Paxlovid (Copackaged) · 11351149 · US
- — Paxlovid (Copackaged) · 11541034 · US
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Paxlovid (Copackaged) CI watch — RSS
- Paxlovid (Copackaged) CI watch — Atom
- Paxlovid (Copackaged) CI watch — JSON
- Paxlovid (Copackaged) alone — RSS
Cite this brief
Drug Landscape (2026). Paxlovid (Copackaged) — Competitive Intelligence Brief. https://druglandscape.com/ci/nirmatrelvir. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing